Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in severe and refractory solar urticaria
NCT02262130Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omalizumab in solar urticaria (SU), sponsored by CHU de Besançon. Primary endpoint: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting). Started Sep 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
solar urticaria (SU)
Beyond the preview
Go deeper on NCT02262130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262130.